Feature | January 16, 2013

Covidien Begins Overseas Launch of Renal Denervation System

The OneShot device offers a solution for physicians treating patients with high blood pressure who fail drug therapy

The OneShot renal denervation system uses a spiral shaped electrode to ablate the renal artery at one time. Most renal denervation catheters require multiple ablations.

January 16, 2013 — Covidien began the commercial launch of the OneShot Renal Denervation System, an over the wire balloon-based irrigated ablation catheter technology for the treatment of hypertension.


Placed percutaneous, OneShot delivers radiofrequency (RF) energy in a circumferential manner to the renal arterial wall, and requires only a single treatment per artery. OneShot received the CE mark in February 2012 and has been undergoing clinical trial evaluation in New Zealand and Europe. The product will be rolled out in Europe, Middle East, Africa, Asia and Latin America over the next several months.

Hypertension affects one billion people worldwide of all ages.1 It occurs when the force of blood pushing against the vessel walls is too high, which can damage the vessels and cause life-threatening conditions. Hypertension is a chronic condition that significantly increases the risk of stroke, heart attack, heart failure and kidney disease.

“Pharmaceutical treatment is the standard of care for hypertensive patients worldwide. Of the hypertension population, 10% to 15% do not adequately respond to medications and are deemed a resistant or refractory hypertension patient,” said Dr. John Ormiston, medical director for Mercy Angiography, Auckland, New Zealand. “These patients are expected to benefit from OneShot, which offers a solution with a much shorter procedure time than with currently available solutions – this could translate into much less pain for patients.”

Covidien’s RHAS (Renal Hypertension Ablation System) feasibility study results were presented by Dr. Ormiston, principal investigator, at the 2012 TCT congress in October 2012. The RHAS study results showed a mean reduction of 42 mmHg at six months, for the eight patients treated with the device in the study. Ormiston has also performed cases with OneShot as part of the RAPID (Rapid renal sympathetic denervation for resistant hypertension using the OneShot system) trial, a 50-patient study currently enrolling in Europe and New Zealand with expected enrollment completion in the early spring timeframe.

For more information: www.covidien.com

 

Reference:

1 The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Bethesda, MD: National Institutes of Health: National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program; May 2003. NIH publication 03?5233.

 

 

Related Content

Mitralign, Percutaneous Tricuspid Valve Annuloplasty System

Mitralign's Percutaneous Tricuspid Valve Annuloplasty System uses catheter delivered pledgeted sutures that can be cinched together to change the valve annulus geometry to help eliminate valvular regurgitation. 

News | Heart Valve Repair| August 31, 2015
August 31, 2015 — Mitralign Inc. said the U.S.
biomimics, 3D stent
News | Peripheral Arterial Disease (PAD)| August 28, 2015
August 28, 2015 — PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania and second in th
iFR, FFR, Philips, Volcano
News | Cath Lab| August 28, 2015
August 28, 2015 — Philips Healthcare is showcasing its latest cardiology solutions at the European Society of Cardiol
News | Heart Failure| August 28, 2015
August 28, 2015 — BioControl Medical said it has completed enrollment in its INOVATE-HF (INcrease Of VAgal TonE in He
News | Hypertension| August 27, 2015
August 27, 2015 — Analysis of blood samples from more than 5,000 people suggests that a more sensitive version of a b
Stent graft, computational fluid dynamics, CFD, stent engineering

In this vector velocity model, brighter colors indicate blood flow acceleration as it passes through a bifurcation. Computation fluid dynamic modeling provides insight on blood flow through and near the walls of the stent graft. Image courtesy of Sanford Health

News | Cath Lab| August 27, 2015
August 27, 2015 — The use of computational fluid dynamics (CFD) modeling has been used for years to better engineer l
News | Cath Lab| August 26, 2015
August 26, 2014 — The Cardiovascular Research Foundation (CRF) announced the late-breaking trials and first report in

Mitral regurgitation viewed under color Doppler. Image courtesy of Toshiba.

Feature | Heart Valve Repair| August 26, 2015
August 25, 2015 — Medtronic announced it entered a definitive agreement to acquire Twelve Inc., a start–up medical de
NuCART, CompView Medical, mobile boom system, cath lab, hybrid OR
Technology | Cath Lab| August 21, 2015
August 21, 2015 — CompView Medical announced the release of the NuCART, a turn-key, all-in-one mobile boom system wit
Corindus, Corpath, radiation dose monitoring, cath lab, vascular robotic system

The Corindus Corpath vascular robotic system.

Technology | Radiation Dose Management| August 19, 2015
Corindus Vascular Robotics Inc. and Unfors RaySafe Inc., a Fluke Biomedical Company, announced a distribution agreement...
Overlay Init